April 29, 2019
Calixar signs exclusive licensing agreement with Regeneron on undisclosed therapeutic target
Calixar has given Regeneron exclusive rights to its technology and expertise to conduct research and discovery of antibodies against an undisclosed target in various therapeutic fields.